Lung Carcinoma Antibody (MOC-32): sc-52345

Lung Carcinoma Antibody (MOC-32) is a mouse monoclonal IgM antibody that detects Lung Carcinoma protein of human origin by western blotting (WB), immunoprecipitation (IP), and immunofluorescence (IF). Anti-Lung Carcinoma antibody (MOC-32) is available as the non-conjugated form. Lung cancer, characterized by the malignant transformation and proliferation of lung tissue, is the most lethal cancer worldwide, accounting for approximately 3 million deaths each year. The disease has seen a rising incidence in women, largely attributed to the increasing number of female smokers, and now represents the leading cause of cancer mortality among women, surpassing breast, ovarian, and uterine cancers combined. The primary risk factor for lung cancer is long-term exposure to inhaled carcinogens, with two major types identified: non-small cell lung carcinoma, which constitutes about 80% of cases, and small-cell lung carcinoma, accounting for roughly 20%. Lung Carcinoma protein plays a crucial role in tumorigenesis and metastasis, as Lung Carcinoma protein is involved in the regulation of cell growth and apoptosis, making Lung Carcinoma protein a significant target for therapeutic intervention. Understanding the structure of Lung Carcinoma protein is vital, as this knowledge can reveal potential sites for drug binding and inform the development of targeted therapies. Treatment strategies are tailored based on the specific cell type of the cancer, the stage of progression, and the individual patient′s health status, highlighting the importance of accurate detection and characterization of lung carcinoma through tools like Lung Carcinoma monoclonal antibody (MOC-32).